{"product_id":"lannett-swot-analysis","title":"Lannett Company SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eLannett's SWOT analysis highlights resilient generic pharma capabilities and cost-efficient manufacturing alongside regulatory exposure, patent cliffs, and margin pressure—critical for investors and strategists assessing risk-return tradeoffs.\u003c\/p\u003e\n\u003cp\u003ePurchase the full SWOT to access a research-backed, editable Word report plus an Excel matrix with actionable recommendations and financial context—ideal for planning, pitching, or investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiverse generic portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiverse generic portfolio spans cardiovascular, CNS, pain and other high-volume categories, stabilizing demand across care settings. Broad product breadth reduces reliance on any single molecule, enabling revenue resilience. Ability to cross-sell into retail, hospital and specialty channels boosts distribution efficiency. Periodic ANDA launches refresh the shelf presence and sustain market access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated manufacturing footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLannett’s integrated manufacturing footprint combines in-house development, manufacturing, packaging and distribution to support tighter cost control and faster time-to-market. Its cGMP-compliant sites underpin consistent quality and regulatory reliability across product lines. Vertical integration strengthens margins and secures supply by reducing third-party dependence. Internal capacity enables rapid scale-up to address shortages or spikes in demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and ANDA execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLannett has a demonstrated track record of submitting and maintaining ANDA approvals and navigating FDA inspections, while undergoing financial restructuring (filed Chapter 11 March 10, 2023). The company has pursued lifecycle management through reformulations, alternative strengths and dosage forms to extend product value. Lannett has engaged in paragraph IV-related strategies and maintains compliance systems designed to reduce approval and remediation risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract manufacturing capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eContract manufacturing and CMO\/CDMO services diversify Lannett revenue by selling capacity to other pharma firms, allowing excess-line utilization to absorb fixed costs and improve margins; external client work under FDA cGMP and third-party audits builds credibility and operational validation, supporting sticky, multi-year supply agreements that stabilize cash flow.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRevenue diversification via CMO\/CDMO\u003c\/li\u003e\n\u003cli\u003eExcess capacity used to absorb fixed costs\u003c\/li\u003e\n\u003cli\u003ecGMP\/third-party credibility\u003c\/li\u003e\n\u003cli\u003ePotential for multi-year supply contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChannel relationships in U.S. generics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLannett maintains long-standing contracts with major U.S. wholesalers, PBMs, GPOs and retail chains, leveraging experience with bid cycles, chargebacks and supply-performance metrics to sustain shelf presence and contract renewals. Service levels — on-time fill and shipment reliability — are positioned as key differentiators, supported by data-driven pricing and inventory controls that improve win rates.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEstablished channel network: wholesalers, PBMs, GPOs, retailers\u003c\/li\u003e\n\u003cli\u003eOperational expertise: bid cycles, chargebacks, supply metrics\u003c\/li\u003e\n\u003cli\u003eService focus: on-time fill, reliability\u003c\/li\u003e\n\u003cli\u003eAnalytics: pricing and inventory supporting contract wins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified generics and CMO\/CDMO operations steady demand after Chapter 11 filing \u003cstrong\u003eMarch 10, 2023\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLannett’s diversified generic portfolio and periodic ANDA launches stabilize demand and reduce single-molecule risk; integrated cGMP manufacturing plus CMO\/CDMO capacity improve margins and secure supply. Established contracts with wholesalers, PBMs, GPOs and retailers and analytics-driven service levels support on-time fills and renewals; filed Chapter 11 March 10, 2023.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRestructuring\u003c\/td\u003e\n\u003ctd\u003eFiled Chapter 11 March 10, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue streams\u003c\/td\u003e\n\u003ctd\u003eGenerics + CMO\/CDMO services\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003eWholesalers, PBMs, GPOs, retailers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a strategic overview of Lannett Company’s internal strengths and weaknesses and external opportunities and threats, mapping competitive position, growth drivers, operational gaps, and market risks to inform strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a focused SWOT snapshot of Lannett to quickly surface regulatory, patent and pricing pain points and highlight strengths for remediation; ideal for fast strategy alignment and executive decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice erosion and thin margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrice erosion in U.S. generics is structural, driven by intense competition and buyer consolidation (the three major wholesalers control roughly 85% of distribution), compressing prices and margins. Lannett remains highly sensitive to GDUFA user fees (a program that raises hundreds of millions annually) plus rebates and chargebacks that materially reduce net realizations. Small cost overruns or recalls can wipe out single-product profits, and the company has limited pricing power versus branded peers. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct concentration risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevenue remains concentrated in a handful of high-volume generic molecules, leaving Lannett dependent on a small product set for the bulk of sales.\u003c\/p\u003e\n\u003cp\u003eCompetitor entries or customer rebids can trigger sudden step-downs in pricing and volume, materially reducing margins on those core products.\u003c\/p\u003e\n\u003cp\u003eCliff risk is pronounced when exclusivity windows or contract terms end, and formulary changes can produce rapid demand shifts that the company is vulnerable to.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply chain dependence on APIs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLannett's API supply chain is highly exposed to India\/China, with industry estimates indicating roughly 70–80% of U.S. generic APIs originate there, raising risks of supplier constraints. Extended lead times, FDA holds or quality events have previously caused multi-week-to-month disruptions. Currency swings and freight cost volatility have pushed COGS higher, and several Lannett SKUs lack robust dual-sourcing, amplifying supply risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConstrained R\u0026amp;D scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eConstrained R\u0026amp;D scale leaves Lannett with fewer shots on goal and a slower pipeline refresh versus larger generic peers moving into complex sterile and high-barrier dosage forms, limiting its ability to enter higher-margin niches. Funding intensive sterile or novel dosage projects strains capital allocation and risks opportunity cost versus diversification into biosimilars or complex generics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmaller R\u0026amp;D footprint reduces pipeline velocity\u003c\/li\u003e\n\u003cli\u003eHigher capital intensity for sterile\/formulation projects\u003c\/li\u003e\n\u003cli\u003eOpportunity cost versus diversification into complex generics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial flexibility pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLannett faces financial flexibility pressures from elevated leverage and near-term refinancing needs common in the generic pharma sector, constraining capital deployment and making covenant compliance a material risk; limited liquidity curtails business development, capacity upgrades, and M\u0026amp;A, while higher interest expense compresses net income. Prolonged price deflation in generics would exacerbate cash-flow stress and amplify refinancing and covenant vulnerability.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLeverage\/refinancing risk\u003c\/li\u003e\n\u003cli\u003eCapital constraints limit BD\/capex\u003c\/li\u003e\n\u003cli\u003eHigher interest expense cuts margins\u003c\/li\u003e\n\u003cli\u003eVulnerable to prolonged price deflation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesalers \u003cstrong\u003e~85%\u003c\/strong\u003e, API \u003cstrong\u003e70-80%\u003c\/strong\u003e drive margin compression\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrice erosion from concentrated wholesalers (~85% share) and GDUFA\/user-fee impacts compress margins; revenue is highly concentrated in a few high-volume generics, creating cliff risk on exclusivities and rebids. API sourcing is exposed (estimated 70–80% U.S. generic APIs from India\/China), and limited R\u0026amp;D\/financing flexibility raises refinancing and capacity risks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesaler share\u003c\/td\u003e\n\u003ctd\u003e~85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI origin\u003c\/td\u003e\n\u003ctd\u003e70–80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGDUFA impact\u003c\/td\u003e\n\u003ctd\u003eHundreds of millions annually\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eLannett Company SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is a real excerpt from the complete Lannett Company SWOT analysis you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the final report. Buy now to unlock the full, editable document.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplex and niche generics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTargeting limited-competition niches—controlled substances (five schedules), modified-release, ophthalmics and injectables—lets Lannett exploit areas with higher formulation, device and sterile manufacturing barriers that support better margins. Sterile injectables require USP 797\/800 and FDA aseptic CGMP compliance, raising entry costs and limiting entrants. Smaller patient populations and specialized delivery forms reduce price erosion versus commodity generics. Leveraging proven regulatory and ANDA experience can accelerate approvals and secure market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpand contract manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExpanding CMO\/CDMO services lets Lannett better utilize plant capacity and stabilize cash flow by capturing parts of the global contract manufacturing market, estimated at about $150 billion in 2024 with ~6% CAGR. Pursuing tech and site transfers plus shortage-mitigation programs can win urgent-volume contracts and reduce downtime. Offering end-to-end development-to-packaging services increases client stickiness through demonstrable quality, lower total cost, and proven reliability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePortfolio refresh via ANDAs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAccelerate ANDA filings in high-velocity oral solids and targeted hospital products to capture share in a market where generics account for about 90% of U.S. prescriptions. Time launches to align with patent expiries and competitor dynamics to maximize first-to-market advantage. Use data analytics to screen molecules with favorable cost-to-compete and differentiate via alternate strengths or pack sizes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic partnerships and in-licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLannett can in-license late-stage molecules from smaller developers lacking U.S. commercialization scale to broaden its pipeline and margins, while co-development agreements distribute technical and regulatory risk on complex launches.\u003c\/p\u003e\n\u003cp\u003eDistribution alliances enable rapid entry into specialty and retail channels; monetizing dormant ANDAs or divesting non-core SKUs recycles capital for higher-return programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIn-license late-stage assets\u003c\/li\u003e\n\u003cli\u003eCo-development to share risk\u003c\/li\u003e\n\u003cli\u003eDistribution alliances for quick channel entry\u003c\/li\u003e\n\u003cli\u003eMonetize ANDAs\/divest non-core SKUs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and shortage programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCapitalize on the FDA's active Drug Shortage list to pursue priority procurement and shortage-response contracts, engaging HHS, VA and state procurement offices to position Lannett as a reliable supplier for multi-year awards; emphasize the company's quality and compliance track record to meet accelerated supply needs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePriority: FDA shortage list engagement\u003c\/li\u003e\n\u003cli\u003eTargets: HHS\/VA\/state contracts\u003c\/li\u003e\n\u003cli\u003eGoal: multi-year awards\u003c\/li\u003e\n\u003cli\u003eEdge: documented quality\/compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTarget sterile injectables \u0026amp; controlled substances; access \u003cstrong\u003e$150B\u003c\/strong\u003e market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTarget sterile injectables, ophthalmics and controlled substances to secure higher margins and limit competition; sterile CGMP\/USP 797-800 barriers raise entry costs. Grow CMO\/CDMO to access the $150B contract manufacturing market (2024, ~6% CAGR) and stabilize cash flow. Accelerate ANDAs (generics ~90% of US scripts) and pursue FDA shortage\/HHS\/VA contracts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eOpportunity\u003c\/th\u003e\n\u003cth\u003e2024 Data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO market\u003c\/td\u003e\n\u003ctd\u003e$150B; ~6% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics share\u003c\/td\u003e\n\u003ctd\u003e~90% US prescriptions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShortage contracts\u003c\/td\u003e\n\u003ctd\u003ePriority FDA list\/HHS\/VA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eT\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehreats\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense competitive rivalry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFace price wars from large generics and aggressive new entrants, with U.S. generics still accounting for about 90% of prescriptions (FDA). Expect rapid multi-supplier commoditization after launch—IQVIA reports price erosion commonly of 30–60% within a year of entry. Major buyers rotate awards, creating bid volatility and sales swings. Margin compression can persist despite volume gains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyer consolidation power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge wholesalers (McKesson, AmerisourceBergen, Cardinal) account for roughly 85% of U.S. distribution and the three biggest PBMs (CVS Caremark, Express Scripts, OptumRx) manage about 80% of prescriptions, giving buyers strong leverage. Rebates, chargebacks and penalties routinely consume double-digit percentage points of gross margin for generics. Single- or dual-award contracts can shift up to 90–100% of volume to winners, so contract losses trigger abrupt revenue drops.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and quality risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFDA inspections, warning letters, or import alerts can force Lannett to halt production, triggering remediation that strains liquidity and delays product launches.\u003c\/p\u003e\n\u003cp\u003eRemediation costs and launch delays compress cash flow and can increase borrowing needs, while heightened regulatory scrutiny on nitrosamines and other impurities raises compliance complexity and CAPEX for testing and controls.\u003c\/p\u003e\n\u003cp\u003eProduct recalls related to quality issues would erode brand reputation and customer trust, potentially reducing market share and pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply chain disruptions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAPI shortages, geopolitical tensions, and port\/logistics bottlenecks can impair Lannett’s fulfillment, extending lead times by up to 30% in recent pharma supply-chain disruptions (2021–24 trends).\u003c\/p\u003e\n\u003cp\u003eCurrency swings and episodic freight spikes have materially raised COGS, squeezing margins amid thin generic pricing.\u003c\/p\u003e\n\u003cp\u003eNatural disasters or pandemics strain inventories and single-source dependencies magnify the operational and financial impact.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLead-time increases: up to 30%\u003c\/li\u003e\n\u003cli\u003eFreight volatility: episodic spikes 2021–24\u003c\/li\u003e\n\u003cli\u003eHigh single-source risk\u003c\/li\u003e\n\u003cli\u003eCurrency-driven COGS pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug pricing policy changes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDrug pricing reforms, including Medicare negotiation under the Inflation Reduction Act (negotiations begin 2026), and growing reimbursement pressure threaten to compress generic net pricing and margins for Lannett; state transparency and price‑gouging mandates in roughly 30 states by 2024 raise compliance costs; shifts in Medicare\/Medicaid mix can lower realized prices, and anti‑shortage\/anti‑consolidation rules add operating complexity and potential cost increases.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedicare negotiation starts 2026 — pricing pressure\u003c\/li\u003e\n\u003cli\u003e~30 states with transparency\/mandates by 2024 — compliance cost\u003c\/li\u003e\n\u003cli\u003eMedicare\/Medicaid mix shift — margin squeeze\u003c\/li\u003e\n\u003cli\u003eAnti‑shortage\/consolidation rules — operational complexity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket squeeze: \u003cstrong\u003e30-60%\u003c\/strong\u003e price erosion as buyers shift volumes, delays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrice erosion 30–60% within a year post-entry (IQVIA); large buyers (wholesalers ~85%, top PBMs ~80%) can shift 90–100% volume via awards; FDA actions, nitrosamine scrutiny and recalls raise remediation\/CAPEX and delay launches. Drug-pricing reforms: Medicare negotiation starts 2026, ~30 states had transparency mandates by 2024. Supply-chain shocks raised lead times up to 30% (2021–24).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRisk\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\/PBMs\u003c\/td\u003e\n\u003ctd\u003e~85% \/ ~80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice erosion\u003c\/td\u003e\n\u003ctd\u003e30–60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead-time rise\u003c\/td\u003e\n\u003ctd\u003eup to 30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098213781852,"sku":"lannett-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/lannett-swot-analysis.png?v=1781799350","url":"https:\/\/pestel-analysis.com\/products\/lannett-swot-analysis","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}